| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells MJ Selby, JJ Engelhardt, M Quigley, KA Henning, T Chen, M Srinivasan, ... Cancer immunology research 1 (1), 32-42, 2013 | 917 | 2013 |
| FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis R Dahan, E Sega, J Engelhardt, M Selby, AJ Korman, JV Ravetch Cancer cell 28 (3), 285-295, 2015 | 521 | 2015 |
| Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells JJ Engelhardt, B Boldajipour, P Beemiller, P Pandurangi, C Sorensen, ... Cancer cell 21 (3), 402-417, 2012 | 346 | 2012 |
| Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology MJ Selby, JJ Engelhardt, RJ Johnston, LS Lu, M Han, K Thudium, D Yao, ... PloS one 11 (9), e0161779, 2016 | 233 | 2016 |
| Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013; 1: 32–42. doi: 10.1158/2326-6066 MJ Selby, JJ Engelhardt, M Quigley, KA Henning, T Chen, M Srinivasan, ... CIR-13-0013, 2013 | 165 | 2013 |
| CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism JJ Engelhardt, TJ Sullivan, JP Allison The Journal of Immunology 177 (2), 1052-1061, 2006 | 157 | 2006 |
| Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. M Selby, J Engelhardt, LS Lu, M Quigley, C Wang, B Chen, AJ Korman Journal of Clinical Oncology 31 (15_suppl), 3061-3061, 2013 | 85 | 2013 |
| A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target ZT Freeman, TR Nirschl, DH Hovelson, RJ Johnston, JJ Engelhardt, ... The Journal of clinical investigation 130 (3), 1405-1416, 2020 | 80 | 2020 |
| Enhancing anti-cancer activity of immunomodulatory fc fusion proteins JJ Engelhardt, AJ Korman, M Quigley, MJ Selby, C Wang | 29 | 2019 |
| Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic I Etxeberria, E Bolaños, A Teijeira, S Garasa, A Yanguas, A Azpilikueta, ... Proceedings of the National Academy of Sciences 118 (26), e2025930118, 2021 | 28 | 2021 |
| Role of FcγRs in antibody-based cancer therapy RF Graziano, JJ Engelhardt Fc Mediated Activity of Antibodies: Structural and Functional Diversity, 13-34, 2019 | 22 | 2019 |
| Abstract SY09-01: Next-generation anti-CTLA-4 antibodies AJ Korman, J Engelhardt, J Loffredo, J Valle, R Akter, R Vuyyuru, ... Cancer Research 77 (13_Supplement), SY09-01-SY09-01, 2017 | 18 | 2017 |
| Correction: Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology MJ Selby, JJ Engelhardt, RJ Johnston, LS Lu, M Han, K Thudium, D Yao, ... PLoS One 11 (11), e0167251, 2016 | 17 | 2016 |
| Improved therapeutic index of an acidic pH-selective antibody PS Lee, KG MacDonald, E Massi, PV Chew, C Bee, P Perkins, B Chau, ... MAbs 14 (1), 2024642, 2022 | 15 | 2022 |
| Anti-ICOS agonist antibodies and uses thereof JJ Engelhardt, MJ Selby, AJ Korman, MD Feingersh, BL Stevens US Patent 10,251,945, 2019 | 14 | 2019 |
| Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys KD Price, F Simutis, A Fletcher, L Ramaiah, R Srour, J Kozlosky, J Sathish, ... Molecular Cancer Therapeutics 17 (1_Supplement), LB-B33-LB-B33, 2018 | 14 | 2018 |
| Anti-ICOS agonist antibodies and uses thereof JJ Engelhardt, MJ Selby, AJ Korman, MD Feingersh, BL Stevens US Patent 10,493,140, 2019 | 13 | 2019 |
| Activatable anti-CTLA-4 antibodies and uses thereof KA Tipton, JW West, S Deshpande, JJ Englehardt US Patent 11,117,968, 2021 | 10 | 2021 |
| Preclinical characterization of BMS-986218, a novel nonfucosylated anti–CTLA-4 antibody designed to enhance antitumor activity J Engelhardt, R Akter, J Loffredo, P So, N Bezman, K Price Cancer Research 80 (16_Supplement), 4552-4552, 2020 | 10 | 2020 |
| The importance of prolonged binding to antigen-presenting cells for T cell fate decisions JJ Engelhardt, MF Krummel Immunity 28 (2), 143-145, 2008 | 9 | 2008 |
